International trends in hepatocellular carcinoma incidence, 1978–2012
Corresponding Author
Jessica L. Petrick
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Slone Epidemiology Center, Boston University, Boston, MA
Correspondence to: Jessica L. Petrick, E-mail: [email protected]Search for more papers by this authorAndrea A. Florio
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorAriana Znaor
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorDavid Ruggieri
Information Management Services, Inc, Rockville, MD
Search for more papers by this authorMathieu Laversanne
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorChristian S. Alvarez
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorJacques Ferlay
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorPatricia C. Valery
QIMR Berghofer Medical Research Institute, Brisbane, Australia
Search for more papers by this authorFreddie Bray
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorKatherine A. McGlynn
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorCorresponding Author
Jessica L. Petrick
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Slone Epidemiology Center, Boston University, Boston, MA
Correspondence to: Jessica L. Petrick, E-mail: [email protected]Search for more papers by this authorAndrea A. Florio
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorAriana Znaor
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorDavid Ruggieri
Information Management Services, Inc, Rockville, MD
Search for more papers by this authorMathieu Laversanne
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorChristian S. Alvarez
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorJacques Ferlay
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorPatricia C. Valery
QIMR Berghofer Medical Research Institute, Brisbane, Australia
Search for more papers by this authorFreddie Bray
Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
Search for more papers by this authorKatherine A. McGlynn
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
Search for more papers by this authorAbstract
Primary liver cancer, the major histology of which is hepatocellular carcinoma (HCC), is the second leading cause of cancer death worldwide. We comprehensively examined recent international trends of primary liver cancer and HCC incidence using population-based cancer registry data. Incidence for all primary liver cancer and for HCC by calendar time and birth cohort was examined for selected countries between 1978 and 2012. For each successive 5-year period, age-standardized incidence rates were calculated from Volumes V to XI of the Cancer Incidence in Five Continents (CI5) series using the online electronic databases, CI5plus. Large variations persist in liver cancer incidence globally. Rates of liver cancer remain highest in Asian countries, specifically in the East and South-East, and Italy. However, rates in these high-risk countries have been decreasing in recent years. Rates in India and in most countries of Europe, the Americas and Oceania are rising. As the population seroprevalence of hepatitis B virus (HBV) continues to decline, we anticipate rates of HCC in many high-risk countries will continue to decrease. Treatment of hepatitis C virus (HCV) is likely to bring down rates further in some high-rate, as well as low-rate, countries with access to effective therapies. However, such gains in the control of liver cancer are at risk of being reversed by the growing obesity and diabetes epidemics, suggesting diabetes treatment and primary prevention of obesity will be key in reducing liver cancer in the longer-term.
Abstract
What's new?
A new analysis of worldwide trends reveals that, between 1978 and 2012, liver cancer rates fell in east Asia and Italy, but rose in India, Europe, and the Americas. In this report, the authors analyzed 35 years of liver cancer incidence, the second leading cause of cancer death worldwide. Using data from the CI5plus database, they calculated incidence rates for 5 year intervals. Although liver cancer rates remained high in east Asia and Italy, they decreased, and are expected to continue to decline as HBV prevalence declines. However, liver cancer rates rose elsewhere, possibly due to increased obesity and diabetes.
Supporting Information
Filename | Description |
---|---|
IJC_32723_Supplemental Material.docxWord 2007 document , 1.1 MB | Appendix S1: Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
- 2Altekruse SF, Devesa SS, Dickie LA, et al. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag 2011; 38: 201–5.
- 3Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017; 67: 302–9.
- 4 Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3: 1683–91.
- 5Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol 2019; 70: 674–83.
- 6McGlynn KA, Petrick JL, London WT. Chapter 33. Liver cancer. In: MJ Thun, MS Linet, JR Cerhan, et al., eds Schottenfeld and Fraumeni cancer epidemiology and prevention, vol. xix. New York, NY: Oxford University Press, 2018. 1308.
- 7Zhang Y, Ren JS, Shi JF, et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer 2015; 15: 94.
- 8Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer 2016; 139: 1534–45.
- 9Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep 2019; 6: 104–11.
- 10Bray F, Colombet M, Mery L, eds. Cancer Incidence in Five Continents, vol. XI (electronic version). Lyon: International Agency for Research on Cancer, 2017. Available from: http://ci5.iarc.fr [accessed: June 10, 2019].
- 11Ferlay J, Colombet M, Bray F. Cancer Incidence in Five Continents, CI5plus: IARC Cancer Base No. 9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2018. Available from: http://ci5.iarc.fr [accessed: June 10, 2019].
- 12Danckert B, Ferlay J, Engholm G, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries. Danish Cancer Society 2019. Available from: http://www.ancr.nu [accessed: June 10, 2019].
- 13Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 2009; 45: 747–55.
- 14Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods part II. Completeness. Eur J Cancer 2009; 45: 756–64.
- 15Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995; 141: 300–4.
- 16Segi M, Fujisaku S, Kurihara M. Geographical observation on cancer mortality by selected sites on basis of standardised death rate. Gann 1957; 48: 219–25.
- 17Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335–51.
10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 18Ferlay J, Rous B. Chapter 4: histological groups. In: F Bray, M Colombet, L Mery, et al., eds Cancer incidence in five continents, Vol XI IARC scientific publication no. 166. Lyon: International Agency for Research on Cancer, 2019.
- 19Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: age-period and age-cohort models. Stat Med 1987; 6: 449–67.
- 20Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet 2012; 3: 268.
- 21Prueksapanich P, Piyachaturawat P, Aumpansub P, et al. Liver fluke-associated biliary tract cancer. Gut Liver 2018; 12: 236–45.
- 22Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013; 34: 1800–5.
- 23Chen JG, Egner PA, Ng D, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013; 6: 1038–45.
- 24Arim RH. Recent status of mycotoxin research in The Philippines. Mycotoxins 2000; 50: 23–6.
- 25WHO vaccine-preventable diseases: monitoring system 2018 global summary, 2018. Third dose of hepatitis B vaccine.
- 26Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 2016; 20: 607–28.
- 27Chang MH, You SL, Chen CJ, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 2016; 151: 472–80 e1.
- 28Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol 2018; 24: 1–9.
- 29Choi J, Han S, Kim N, et al. Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. Hepatology 2017; 66: 1454–63.
- 30Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067–77.
- 31Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148: 820–6.
- 32Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584–9.
- 33Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327–32.
- 34 Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morb Mortal Wkly Rep 2012; 61: 6.
- 35Joy JB, McCloskey RM, Nguyen T, et al. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. Lancet Infect Dis 2016; 16: 698–702.
- 36Mora MV, Romano CM, Gomes-Gouvea MS, et al. Molecular characterization, distribution, and dynamics of hepatitis C virus genotypes in blood donors in Colombia. J Med Virol 2010; 82: 1889–98.
- 37Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–21.
- 38Federico Hinestrosa F, Marín JI, Maya OM, et al. Update of hepatitis C in Colombia. Curr Trop Med Rep 2018; 5: 133–7.
10.1007/s40475-018-0147-5 Google Scholar
- 39Trickey A, Fraser H, Lim AG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol 2019; 4: 435–44.
- 40Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4–14.
- 41World Health Organization. Fact Sheet on Overweight and Obesity, 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [accessed: November 20, 2018].
- 42Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. Report on the most recent prevalence estimates of non-alcoholic fatty liver disease in Asian populations. J Hepatol 2017; 67: 862–73.
- 43Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681–8.
- 44Ramachandran A, Chamukuttan S, Shetty SA, et al. Obesity in Asia–is it different from rest of the world. Diabetes Metab Res Rev 2012; 28(Suppl 2): 47–51.
- 45Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016; 122: 1757–65.
- 46Mourad M, Masri L. Millions flock to free tests as Egypt seeks to eradicate hepatitis C. London: Reuters, 2018.
- 47Lemoine M, Eholie S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol 2015; 62: 469–76.
- 48 WHO. WHO fact sheet on hepatitis B. Geneva: WHO, 2018.
- 49Graber-Stiehl I. The silent epidemic killing more people than HIV, malaria or TB. Nature 2018; 564: 24–6.
- 50Liu Y, Chang CC, Marsh GM, et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer (Oxford, England: 1990) 2012; 48: 2125–36.
- 51Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009; 286: 22–8.
- 52Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 29: iv238–55.
- 53Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68: 723–50.
- 54Ferlay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries (IARC/IACR tools for cancer registries). Technical Report No. 42. Lyon: IARC, 2005.